Event Type
Disclosure
Voluntary
Variant
8-K
Other Events. In connection with the merger (the “Merger”) with Cyclo Therapeutics, Inc. (“Cyclo”), Rafael Holdings, Inc. (the “Company”) issued 1,078,796 warra